What is PDUFA?
The Prescription Drug User Fee Act (PDUFA) sets deadlines for FDA decisions on new drug applications. When a drug sponsor submits an NDA or BLA, the FDA commits to a decision date (typically 10 months for standard review, 6 months for priority review). That date is the PDUFA date.
Why PDUFA Dates Matter
The FDA's yes/no decision on a major drug can move a biotech stock 30-80% in a single session. For small-cap biotechs with only 1-2 pipeline assets, PDUFA decisions are often make-or-break.
Possible Outcomes
Approval (positive)
Stock typically rises 20-50%. Extent depends on how much approval was priced in. Surprise approvals after CRLs can trigger 100%+ moves.
Complete Response Letter (CRL)
The FDA declines to approve and requests more information. Typically triggers 30-60% declines. Some CRLs are manageable (request for more data), others fatal (fundamental efficacy or safety concerns).
Delay (extension of PDUFA date)
Neither approval nor denial; FDA extends review. Usually results in 10-30% drops.
Approval with restrictions
Narrower label than hoped (fewer indications, stricter patient population). Muted positive reaction.
How to Prepare for a PDUFA Event
Check the FDA Advisory Committee (AdCom) vote
If an AdCom voted on the drug, the vote is a strong leading indicator. Unanimous yes = likely approval. Split votes = uncertainty; often sharply negative outcomes.
Compare to class precedent
Has the FDA approved similar drugs in this class before? What label language did they use?
Watch for PDUFA-related news
- FDA labeling negotiations leaked
- Company guidance changes
- Insider buying or selling
- Short interest changes
Implied Volatility Spike
Options IV typically spikes 3-5x in the 2 weeks before PDUFA dates. This reflects the binary outcome risk. After the decision, IV crushes back to baseline.
Trading Patterns
Pre-PDUFA runup
Biotechs often rally 10-20% into PDUFA dates on option-driven buying. Some investors sell into this rally to avoid binary risk.
Post-PDUFA IV crush
Straddles bought before PDUFA often lose value even if the stock moves the expected amount, because IV collapse eats premium.
"Sell the news" on approval
Sometimes approvals are fully priced; stock falls on the news because the setup was crowded.
Risk Management
- Position sizing: treat PDUFA positions as binary bets
- Never concentrate portfolio in single biotech pre-PDUFA
- Collars and spreads can limit downside while retaining upside
- Post-CRL: don't average down immediately; many CRL stocks fall further in subsequent weeks
Data Sources
- FDA drug approvals calendar: [fda.gov](https://www.fda.gov)
- BiopharmCatalyst: specialized PDUFA tracker
- [/topic/biotech-fda](/topic/biotech-fda) live feed
Key Takeaways
- PDUFA = FDA decision deadline, typically 6-10 months post-submission
- Approval / CRL / delay outcomes each have characteristic price action
- Options IV spikes pre-PDUFA and crushes post
- Position-size for binary outcomes
- AdCom vote is a strong leading indicator
See [/glossary/pdufa](/glossary/pdufa), [/glossary/crl](/glossary/crl), [/glossary/adcom](/glossary/adcom).